- Home
- ALLO
as 12-17-2024 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 431.9M | IPO Year: | 2018 |
| Target Price: | $10.06 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $5.78 | Next Earning Date: | 11-07-2024 |
| Revenue: | $43,000 | Revenue Growth: | 26.47% |
| Revenue Growth (this year): | -37.05% | Revenue Growth (next year): | -27.29% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MESSEMER DEBORAH M. | ALLO | Director | Dec 9 '24 | Sell | $2.18 | 9,136 | $19,916.48 | 157,629 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
6 days ago
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Zacks
16 days ago
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
Zacks
23 days ago
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
GlobeNewswire
a month ago
Allogene Therapeutics Announces Participation in December Investor Conferences
GlobeNewswire
a month ago
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Zacks
a month ago
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Zacks
a month ago
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.